Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2015

01-08-2015 | Original Article

Expression and role of V1A subunit of V-ATPases in gastric cancer cells

Authors: Pengfei Liu, Haijiao Chen, Lanxiu Han, Xiaoping Zou, Weidong Shen

Published in: International Journal of Clinical Oncology | Issue 4/2015

Login to get access

Abstract

Background

Vacuolar-ATPases (V-ATPases) play an important role in maintaining a relatively neutral pHi (internal pH) and are responsible for the progression of cancer. V-ATPases contain different subunits and few studies have been conducted on subunit V1A. This study aimed to investigate the gene expression of V1A subunit of V-ATPases in gastric cancer tissues and explore its role in the progression and prognosis of gastric cancer.

Methods

The protein expressions of the V1A subunit of V-ATPase gene in 100 normal gastric specimens and 100 gastric cancer tissues were determined by immunohistochemistry. The role of V1A subunit of V-ATPases was studied using a specific small interfering RNA (siRNA).

Results

The positive expression rate of the V1A subunit of V-ATPases was 76 % in gastric cancer tissue samples, much higher than that in normal tissue samples (30 %, P < 0.05), and was correlated with histological grade (P = 0.001), lymph node metastasis (P = 0.002), TNM (P = 0.040), and vascular invasion (P = 0.010), but not with patient age, sex, depth of tumor invasion, tumor size, or histological type. The median overall survival times of 76 patients who had positive staining for tumor cell V1A subunit of V-ATPases and 24 patients who had negative staining were 31.7 and 59.2 months, respectively. When the expression of V1A subunit was knocked down using siRNA, the proliferation and invasion of gastric cancer cells in vitro were significantly inhibited.

Conclusions

V1A subunit of V-ATPases can be a prognostic indicator for poor outcome and is a therapeutic target in gastric cancer.
Literature
1.
Parkin DM, Bray F, Ferlay J et al (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74–108PubMedCrossRef
2.
3.
Kapadia CR (2003) Gastric atrophy, metaplasia, and dysplasia: a clinical perspective. J Clin Gastroenterol 36:S29–S36PubMedCrossRef
4.
Hinton A, Bond S, Forgac M (2009) V-ATPase functions in normal and disease processes. Pflugers Arch—Eur J Physiol 457:589–598CrossRef
5.
Perez-Sayans M, Suarez-Penaranda JM, Barros-Angueira F et al (2012) An update in the structure, function, and regulation of V-ATPases: the role of the C subunit. Braz J Biol 72:189–198PubMedCrossRef
6.
Petzoldt AG, Gleixner EM, Fumagalli A et al (2013) Elevated expression of the V-ATPase C subunit triggers JNK-dependent cell invasion and overgrowth in a Drosophila epithelium. Dis Model Mech 6:689–700PubMedCentralPubMedCrossRef
7.
Sermoune SR, Bakunis K (2004) Vacuolar H+-ATPase in human breast human cancer cells with distinct metastatic potential: distribution and functional activity. Am J Physiol Cell Physiol 286:C1443–C1452CrossRef
8.
Sasazawa Y, Futamura Y, Tashiro E et al (2009) Vacuolar H+-ATPase inhibitors overcome Bcl-xL mediated chemoresistance through restoration of a caspase-independent apoptotic pathway. Cancer Sci 100:1460–1467PubMedCrossRef
9.
De Milito A, Fais S (2005) Tumor acidity, chemoresistance and proton pump inhibitors. Future Oncol 1:779–786PubMedCrossRef
10.
Hurtado-Lorenzo A, Skinner M, El Annan J et al (2006) V-ATPase interacts with ARNO and Arf6 in early endosomes and regulates the protein degradative pathway. Nat Cell Biol 8:124–136PubMedCrossRef
11.
Lu X, Qin W, Li J et al (2005) The growth and metastasis of human hepatocellular carcinoma xenografts are inhibited by small interfering RNA targeting to the subunit ATP6L of proton pump. Cancer Res 65:6843–6849PubMedCrossRef
12.
Hinton A, Bond S, Forgac M (2009) V-ATPase functions in normal and disease processes. Pflugers Arch 457:589–598PubMedCrossRef
13.
Clouston AD (2001) Timely topic: premalignant lesions associated with adenocarcinoma of the upper gastrointestinal tract. Pathology 33:271–277PubMedCrossRef
14.
Lim JH, Park JW, Kim MS et al (2006) Bafilomycin induces the p21-mediated growth inhibition of cancer cells under hypoxic conditions by expressing hypoxia-inducible factor-1alpha. Mol Pharmacol 70:856–865CrossRef
15.
Hong J, Yokomakura A, Nakano Y et al (2006) Inhibition of vacuolar-type (H+)-ATPase by the cytostatic macrolide apicularen A and its role in apicularen A-induced apoptosis in RAW 264.7 cells. FEBS Lett 580:2723–2730PubMedCrossRef
16.
Wojtkowiak JW, Rothberg JM, Kumar V et al (2012) Chronic autophagy is a cellular adaptation to tumor acidic pH microenvironments. Cancer Res 72:3938–3947PubMedCentralPubMedCrossRef
17.
Huss M, Sasse F, Kunze B et al (2005) Archazolid and apicularen: novel specific V1A subunit of V-ATPases inhibitors. BMC Biochem 6:1–13CrossRef
18.
Pérez-Sayáns M, Somoza-Mart JM, Barros-Angueira F et al (2009) V-ATPases inhibitors and implication in cancer treatment. Cancer Treat Rev 35:707–713PubMedCrossRef
19.
Chen M, Zou X, Luo H et al (2009) Effects and mechanisms of proton pump inhibitors as a novel chemosensitizer on human gastric adenocarcinoma (SGC7901) cells. Cell Biol Int 33:1008–1019PubMedCrossRef
20.
De Milito A, Iessi E, Logozzi M et al (2007) Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase independent mechanism involving reactive oxygen species. Cancer Res 67:5408–5417PubMedCrossRef
21.
Dooley CM, Schwarz H, Mueller KP et al (2013) Slc45a2 and V-ATPase are regulators of melanosomal pH homeostasis in zebrafish, providing a mechanism for human pigment evolution and disease. Pigment Cell Melanoma Res 26:205–217PubMedCrossRef
22.
Sennoune SR, Luo D, Martinez-Zaguilan R (2004) Plasmalemmal vacuolar-type H(+)-ATPase in cancer biology. Cell Biochem Biophys 40:185–206PubMedCrossRef
23.
Tabares L, Betz B (2010) Multiple functions of the vesicular proton pump in nerve terminals. Neuron 68:1020–1022PubMedCrossRef
24.
Beyenbach KW, Wieczorek H (2006) The V-type H+ ATPase: molecular structure and function, physiological roles and regulation. J Exp Biol 2009:577–589CrossRef
25.
Garcia-Garcia A, Perez-Sayans Garcia M, Rodriguez MJ et al (2012) Immunohistochemical localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous cell cancer and normal oral mucosa. Biotech Histochem 87:133–139PubMedCrossRef
Metadata
Title
Expression and role of V1A subunit of V-ATPases in gastric cancer cells
Authors
Pengfei Liu
Haijiao Chen
Lanxiu Han
Xiaoping Zou
Weidong Shen
Publication date
01-08-2015
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 4/2015
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-015-0782-y

Other articles of this Issue 4/2015

International Journal of Clinical Oncology 4/2015 Go to the issue

Review Article

Recent advances in robotic surgery for rectal cancer

Original Article

Increased levels of sperm protein 17 mRNA and circulating antibodies in periampullary carcinoma patients

Original Article

Transoral robotic surgery in management of oropharyngeal cancers: a preliminary experience at a tertiary cancer centre in India

Original Article

Differences in adverse event profiles between everolimus and temsirolimus and the risk factors for non-infectious pneumonitis in advanced renal cell carcinoma

Original Article

Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer

Original Article

Outcomes of abdominal radical trachelectomy: results of a multicenter prospective cohort study in a Tohoku Gynecologic Cancer Unit
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits